Patrys has assembled an international panel of critical care specialists to steer the development of RLS-2202, its injectable formulation of quetiapine for delirium in acute-care settings.
The Perth-based clinical-stage company announced that it had established a Clinical Advisory Committee spanning Australia, the United States and Europe. The move comes as its Phase 1 program in healthy volunteers gets underway, and planning begins for evaluation in patients with delirium.
The committee will advise on trial design, patient selection and endpoints, treatment standards and real-world clinical practice, and help connect the company with leading clinical centres.
"We are delighted to welcome Dr Iliff, Professor Devlin and Professor van den Boogaard to our Clinical Advisory Committee. Their collective expertise will be instrumental as we advance RLS-2202 through clinical development, helping to ensure our trials are designed and executed to the highest scientific and clinical standards," chief executive Dr Samantha South said. The appointments, she added, reflect "continued focus on strengthening its clinical and academic leadership in critical care, delirium research and education."
Chairing the committee is Dr Johnny Iliff, an emergency physician at Royal Perth Hospital and St John of God Murdoch Hospital and an aeromedical consultant for the Royal Flying Doctor Service. His remit extends across the company's broader pipeline, focusing on whether recommendations are feasible and safe in critically ill patients.
"Delirium remains a significant challenge in acute and critical care, and developing new treatment options requires clinical studies that reflect the complexities of treating these patients in real-world settings," Dr Iliff said.
Professor John W. Devlin holds posts at Northeastern University, Brigham and Women's Hospital and Harvard Medical School, and researches the detection, prevention and treatment of delirium, including the efficacy and safety of antipsychotics. He chaired the Society of Critical Care Medicine's 2018 international PADIS guidelines, a cornerstone framework for ICU delirium management, helped lead the society's ICU Liberation collaborative, is a past president of the American Delirium Society and co-directs the NIH-funded NIDUS network.
"Despite the significant burden of delirium in critically ill patients, treatment options remain limited and there continues to be a need for well-designed clinical research in this area," he said.
The European seat goes to Professor Mark van den Boogaard, Professor of Nursing Science in Acute and Intensive Care at Radboudumc in Nijmegen. He developed the widely used (E-)PRE-DELIRIC prediction model, co-leads the MONITOR-IC study following more than 20,000 ICU survivors across eight Dutch hospitals, sits on the European Delirium Association executive board and contributed to both the 2018 US and 2024 Dutch ICU guidelines.
"Delirium is a complex condition and careful consideration of patient selection, clinically meaningful endpoints and the realities of intensive-care practice will be important in designing future studies," he said.
Dr Iliff covers whether a trial can be run in a busy Australian acute-care ward. Professor Devlin brings trial experience with sedatives and antipsychotics plus US guideline and implementation credentials relevant to the company's FDA strategy. Professor van den Boogaard covers European practice, trial considerations, and research networks relevant to regulatory and adoption questions there.
Patrys said the committee will provide "an internationally informed perspective across the regulatory, adoption/reimbursement, and clinical trial environments of its key target jurisdictions."
